Our Vision

Combinati believes simplicity shouldn’t require sacrificing robustness, quality or rigor – in fact, it should enable it. Our easy-to-use digital PCR platform offers absolute quantification to track disease-relevant biomarkers over time with high accuracy and precision. Comprised of a single instrument and a single consumable, the core microfluidic technology enables partitioning of samples with minimal waste. Combined with the ability to robustly reject false positives and easily adapt traditional qPCR assays, Combinati aims to democratize digital PCR for researchers all over the world.

Our Team

Paul Hung Combinati

Paul Hung, Ph.D.

CEO, Co-Founder

Paul is an entrepreneur specializing in microfluidic platform technology development. He has 14 years of life science leadership experience in product development, R&D management, and bringing innovation from lab to marketplace. He was the co-founder and CTO of CellASIC, which was acquired by Merck KGaA, and served as the Head of Microfluidics in the Life Science Workflow division. He received his PhD in Electrical Engineering and Computer Science from UC Berkeley, and B.S. degree in Electrical Engineering from National Taiwan University.

Andrew Zayac Combinati

Andrew Zayac

Engineering, Co-Founder

Having worked at startups and large companies in life science markets, Andrew has broad development and engineering background including biology, design, microfluidics, optics, pneumatics, mechanical systems, and user experience. His agility lets him contribute across the board so that the team as a whole can deliver products that just work.

Company Awards

National Institute of Health Small Business Innovative Research Grant

Combinati is the recipient of three grants provided by the NIH to create innovative technologies to improve human health. These programs recognize and support companies breaking into the federal R&D arena, creating life-saving technologies, and stimulating economic growth.

SLAS 2018 Innovation Award

Paul Hung, PhD of COMBiNATi, Inc. was awarded with the the SLAS Innovation Award in recognition of his exceptional podium presentation at the SLAS Annual Conference, Microfluidic Siphoning Array (MSA) – A Novel Scalable Digital PCR Integrated Platform.

AACC 2020 Academy’s Distinguished Abstract Award

Two abstracts were submitted and won the AACC Distinguished Abstract award. The first highlighted the development and validation of a multiplexing dPCR Spinal Muscular Atrophy (SMA) screening assay on the Absolute Q. The second covered a 4-color multiplexing dPCR assay for Non-Invasive Prenatal Trisomy testing, also using the Absolute Q.

Peer-Reviewed Publications

Nature Scientific Reports logo

Precision cancer monitoring using a novel, fully integrated, microfluidic array partitioning digital PCR platform

The Absolute Q is a single instrument digital PCR platform with a novel approach for reagent partitioning on a low cost plate. Here, the Absolute Q was used to quantify levels of a novel gene-fusion in liquid biopsy samples and ultimately track a cancer patient’s response to therapy and eventual remission.

Read More

Patents

  • 9,845,499: Microfluidic Siphoning Array for Nucleic Acid Quantification
  • 10,252,266: Mircofluidic Siphoning Array for Nucleic Acid Quantification
  • 10,519,494: Methods and Systems for Nucleic Acid Analysis and Quantification

Contact Us